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Abstract
Background: Spinal Muscular Atrophy (SMA) is an autosomal recessive disease that leads to specific loss of motor neurons.
It is caused by deletions or mutations of the survival of motor neuron 1 gene (SMN1). The remaining copy of the gene, SMN2,
generates only low levels of the SMN protein due to a mutation in SMN2 exon 7 that leads to exon skipping.
Methodology/Principal Findings: To correct SMN2 splicing, we use Adenovirus type 5–derived vectors to express SMN2-
antisense U7 snRNA oligonucleotides targeting the SMN intron 7/exon 8 junction. Infection of SMA type I–derived patient
fibroblasts with these vectors resulted in increased levels of exon 7 inclusion, upregulating the expression of SMN to similar
levels as in non–SMA control cells.
Conclusions/Significance: These results show that Adenovirus type 5–derived vectors delivering U7 antisense
oligonucleotides can efficiently restore full-length SMN protein and suggest that the viral vector-mediated oligonucleotide
application may be a suitable therapeutic approach to counteract SMA.
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Introduction
Spinal Muscular Atrophy is a neurodegenerative disease that
is caused by mutations or deletions in the survival of motor neuron
1 (SMN1) gene [1]. Chromosome 5q13 carries two nearly
identical copies of the SMN gene, SMN1 and SMN2. Both genes
code for the same protein, but a C to T transition in the 59
region of SMN2 exon 7 results in an altered splicing pattern,
where the predominant product lacks exon 7 [2]. Proteins
translated from these mRNAs are unstable and not functional.
Only 20% of the SMN2 transcripts contain exon 7 and code for
functional full-length SMN protein [1]. It is believed that low
amounts of functional protein derived from the SMN2 gene are
sufficient for most tissues in the developing organism, but not
for motoneurons where the SMN protein is expressed at about
100-fold higher levels during embryonic development [3,4].
The specific function of SMN in motoneurons is not yet fully
understood, but the disease might be linked to deficiencies in
pre-mRNA splicing in developing motoneurons [5,6,7,8,9].
The 38 kDa SMN protein, which is part of the SMN complex,
has been shown to play a major role in the biogenesis and
recycling of snRNPs, essential components of the spliceosome
[7,10,11].
To overcome the imbalance in the SMN2 splicing pattern, we
designed antisense RNA oligonucleotides to block the 39 splice site
of SMN exon 8. In the presence of these antisense molecules exon
7 inclusion can be induced [12], even when these RNA
oligonucleotides were expressed in the context of murine U7
snRNAs [13] (Figure 1A). The native U7 snRNP particle contains
an RNA molecule that base pairs with histone pre-mRNA [14].
We exchanged the anti-histone base pairing sequence with an anti-
SMN exon 8 antisense sequence. Furthermore, the murine Sm
binding sequence was replaced with the human Sm binding
sequence to avoid cleavage of the targeted sequences [14,15].
In this study, we use Adenovirus type 5-derived expression
vectors to deliver modified U7 snRNAs containing SMN exon 8
antisense sequences. We demonstrate that expression of these
snRNAs in tissue cultures transiently transfected with SMN2
minigenes results in increased levels of mRNA transcripts
including SMN exon 7. Infection of SMA type I patient derived
cells with the U7 antisense oligonucleotide expressing vectors leads
to elevated exon 7 inclusion ratios as well as increased levels of
full-length SMN protein.
Materials and Methods
Generation of adenovirus type 5 vectors
U7-antisense RNP encoding sequences were amplified by PCR
from previously generated U7-antisense cDNAs [13] and cloned
into the pLAD shuttle vector [16]. The resulting shuttle vector
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AdV-5 viral genome lacking the E1 gene into HEK 293 Adv E1
transgenic cells. This co-transfection allowed homologous recom-
bination of the U7-antisense sequence into the viral genome and
production of viral particles. Cells were harvested 10 days post
transfection. To purify virus, cells were frozen/thawed 3 times and
subsequently sonicated. Virus stock concentrations were deter-
mined by plaque assay.
Determination of exon 7 inclusion levels
For analysis of U7 antisense snRNP effects on SMN1 and
SMN2 splicing, HeLa cells were passaged in 10% FBS media
and transfected with cDNAs encoding either minigene.
24 hours post transfection cells were transformed with
adenoviral vectors expressing the different U7 antisense
snRNP sequences or with control vectors at an MOI of 20.
Cells were passaged for 7 days. The ratio of exon 7 containing
transcripts versus those lacking exon 7 was determined by RT-
PCR after extraction of total RNA from transfected cell
cultures using minigene specific primers. Quantitation of gel
purified PCR products was carried out using the BioRad
Quantity One software. The effect of U7 antisense snRNPs on
endogenous SMN transcripts was evaluated in Spinal Muscular
Atrophy type 1-derived patient fibroblast cells (Coriell Institute
GM 3813) and compared to fibroblast cell cultures derived
from the patient’s healthy mother (Coriell Institute GM3814).
Cells were grown in DMEM media containing 10% FBS for
24 hours before transformation with U7 antisense snRNP
expressing Adv-5 vectors or control virus not expressing
antisense sequences. After transformation, cell cultures were
grown in 2% FBS media. Ten days post infection cells were
harvested and total RNA was extracted for semi-quantitative
RT-PCR analysis. An exon 6 forward and exon 8 reverse
primer set was used for amplification of SMN transcripts.
Analysis of SMN protein expression
Adv-5 transformed cell cultures or un-transformed control cells
were harvested 10 days post transfection and analyzed for SMN
protein expression levels by quantitative western blotting. For
detection of the SMN protein a BD biosciences monoclonal
antibody against SMN was used. Expression levels were normalized
to b-Actin expression levels using an anti-Actin monoclonal
antibody (Sigma). Quantification was performed using Bio-Rad’s
Quantity one software.
Quantification of SMN protein positive Gemini of Cajal Bodies
was performed by immunofluorescence analysis. Patient derived
fibroblasts or control cells were grown on cover slips and
transformed with U7 snRNP expressing vectors or control vectors
24 hours later. Cells were subsequently grown in DMEM media
with 2%FBS for 10 days. For analysis the cell cultures were fixed
with 3% paraformaldehyde. SMN localization in nuclear gems
was visualized with a monoclonal anti SMN antibody (BD
Biosciences) and a Cyanine 3-labeled secondary antibody (sigma).
Gem-positive cells were counted in multiple experiments for
statistical analysis.
Results
To make the U7 snRNA methodology more amendable for
gene therapy approaches, we generated Adenovirus type 5-derived
vectors that constitutively express modified U7 snRNAs. Based on
our previous findings, we selected 5 different anti-SMN sequences
that demonstrated promising effects on upregulating exon 7
inclusion (Figure 1B) [13]. To determine the efficacy of these viral
vectors, HeLa cells were transfected with SMN2 minigenes and
subsequently transduced with anti-SMN U7 snRNA expressing
Adenovirus. In agreement with our previous studies, all vectors
expressing an anti-SMN U7 sequence resulted in an increase in
exon 7 inclusion levels from 33% up to 60% (Figure 2). With the
Figure 1. Antisense U7 snRNA strategy and selection of
antisense oligonucleotides for Adenovirus delivery. (A) The
modified U7 snRNA contains a sequence complementary to the 39
splice site of SMN exon 8. In addition, the wild-type murine U7 Sm
binding sequence was replaced with the human consensus Sm binding
sequence (SmOpt) to inactivate target cleavage [15]. (B) Nucleotide
sequence and target location of the five different antisense oligonu-
cleotides chosen for Adv-5 vector-derived delivery.
doi:10.1371/journal.pone.0008204.g001
Figure 2. Effect of antisense U7 snRNAs delivered by Adv-5
vectors on SMN2 minigenes. HeLa cells were transiently transfected
with either SMN2 or SMN1 minigenes spanning exons 6 through 8.
12 hours post transfection tissue cultures were transduced with Adv-5/
antisense U7 snRNAs or control vectors (SmOpt, GFP) at a MOI of 20.
The bar summarizes exon 7 inclusion levels observed from 7
independent experiments. Standard deviations are shown for each
series. An asterisk above bars indicates a statistically significant
difference between the experimental series and the SmOpt control
series. A statistically significant difference between series is defined by
p-values ,0.005.
doi:10.1371/journal.pone.0008204.g002
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significant (p-values #0.005) when compared to uninfected cells or
cells that were infected with control vectors either expressing U7
particles that include an antisense oligonucleotide sequence against
the unrelated histone mRNA or expressing GFP. Based on
multiple experiments, anti-SMN U7 snRNA vector C was most
efficient in upregulating exon 7 containing transcripts, whereas
vector B had the least effect. Transduction with control vectors
resulted in a reduced and not highly significant increase in exon 7
inclusion (40% exon 7 inclusion, p-value=0.05 for SmOpt and
38% exon 7 inclusion, p-value=0.11 for GFP). Taken together,
these results indicate that delivery of antisense U7 snRNAs by
Adenovirus type 5-derived vectors has a similar efficacy in
modulating the splicing pattern of SMN2 minigenes as transient
transfection of antisense U7 snRNA expressing cDNAs.
To investigate whether antisense U7 snRNAs can also modify
the splicing pattern of the endogenous SMN2 gene, we used a
SMA patient fibroblast cell line (GM3813). These cells have no
functional SMN1 gene and only two copies of the SMN2 gene [17].
Therefore, all SMN protein detected in these cells, full-length and
truncated, is generated from the SMN2 gene copies. In contrast,
higher levels of functional SMN protein are produced in GM3814
cells, a fibroblast cell line derived from the mother of the SMA
patient, due to the presence of one intact copy of the SMN1 gene.
The expression difference between these cell lines has been used as
a benchmark to define sufficient SMN expression because the
carrier does not show defects in motoneuron outgrowth. The
patient-derived cell line GM3813 was infected with Adv-5 vectors
encoding different antisense U7 oligonucleotides at a MOI of 20
and GM3814 cells were used as a reference (Figure 3). All cell
cultures infected with antisense U7 snRNA-expressing vectors
displayed significantly increased ratios of exon 7 containing splice
products compared to the uninfected patient cell line or the
control GFP and SmOpt vectors (p-values #0.005), with
sequences C and D being the most efficient (Figure 3). In contrast,
cell cultures transduced with Adv-5 control vectors GFP and
SmOpt showed no statistically significant increase in exon 7
inclusion levels compared to uninfected GM3813 cells (Figure 3)
(p-values $0.4). We conclude that anti-SMN U7 snRNA
expression in SMA type I fibroblasts can increase the ratio of
exon 7 inclusion to levels comparable to healthy carrier
individuals.
Previous studies demonstrated that the protein produced
from the truncated transcript of the SMN2 gene is unstable and
not fully functional [18,19,20], as indicated by the presence of
SMN in nuclear gems, a concentrated compartment of the
SMN complex [21]. Compared to healthy individuals, most
SMA type I patient-derived fibroblast cells have no or very
limited amounts of SMN containing nuclear gems [22]. To
address the question whether infection by Adv-5 antisense U7
snRNAs results in increased levels of full-length SMN protein,
we determined the percentage of gem-positive cells in Adv-5/
U7 snRNA transduced tissue cultures (Figure 4A). As a
reference, the percentage of gem-positive cells was also
determined in uninfected GM3813 patient and GM3814
mother cell cultures. Ten days after infection, all anti-SMN
U7 expressing cell cultures except those infected with vector B
displayed statistically significant increases in nuclear gem
counts compared to patient cell lines that were infected with
SmOpt or GFP control vectors (Figure 4B) (p-values #0.05
when compared to SmOpt). As expected from their efficiency
to upregulate exon 7 inclusion, anti-SMN U7 sequences A, C
and D showed the highest percentage of gem-positive cells at
levels comparable to those observed in uninfected parental
control cells (3814). These data indicate that full-length SMN
protein expression was elevated to the level of a healthy
individual. For further validation we performed western blot
analysis to measure SMN protein levels in cell cultures treated
with antisense U7 snRNPs. Relative levels of SMN protein
were determined by normalization to b-Actin levels. Our
results show a noticeable increase of total SMN protein levels
in cells treated with antisense U7 snRNPs over uninfected cell
cultures (Figure 4C). We conclude that antisense U7 snRNAs
delivered by Adv-5 vectors induces the expression of functional
SMN protein in cell cultures.
Discussion
Using the Adenoviral vector tool enabled us to study the
effects of anti-SMN U7 snRNAs on endogenous SMN
expression in SMA type I patient fibroblasts. These cells have
no functional SMN1 gene and contain only two copies of SMN2
[17]. Transduction of these cells with antisense U7 snRNA-
expressing vectors resulted in elevated ratios of transcripts
containing exon 7 (Figure 3). In earlier studies we showed that
skipping of exon 7 results from a competition between the 39
splice sites of intron 7 and 8. Significantly, targeting the intron
83 9 splice site with antisense oligonucleotides resulted in
preferred use of the intron 7 39 splice site and, thus, in elevated
levels of exon 7 inclusion [12]. The fact that full-length SMN
protein levels were restored to those in a healthy carrier
(Figure 4) supports the notion that the antisense approach can
be considered as a potential therapeutic strategy for the
treatment of SMA. Application of either a nonspecific
antisense oligonucleotide coding U7 particle or a particle
encoding GFP resulted in a small increase of exon 7 inclusion
rates (Figure 2 and Figure 4). This is most likely due to a
nonspecific effect of the AdV-5 vector, because application of
theses modified U7 particles by transfection does not result in
such an increase [12,13].
The presence of nuclear gems is a commonly accepted measure
to quantify levels of SMN protein in a cell, as SMN is an essential
component of these nuclear structures [21,23]. Immunofluores-
cence staining of SMN revealed that the percentage of gem-
positive cells was significantly increased after transduction with
Adv-5/antisense U7 snRNAs (Figure 4). These observations and
Figure 3. Evaluation of endogenous SMN splicing patterns in
SMA type I patient-derived fibroblasts. SMA type I 3813 cells were
transduced with Adv-5 vectors expressing antisense U7 snRNAs or
control vectors (GFP, SmOpt) at a MOI of 20. Cells were passaged for 10
days in 2% FBS medium, and then harvested for RNA extraction. The bar
graph gel image summarizes the levels observed from 8 independent
experiments. Standard deviations are shown for each series. An asterisk
above bars indicates a statistically significant difference between the
experimental series and the SmOpt control series. A statistically
significant difference between series is defined by p-values ,0.005.
doi:10.1371/journal.pone.0008204.g003
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blocking the exon 8 39 splice site of SMN2 can restore SMN levels
in patient cell lines to those observed in carrier cell lines. However,
while the increase in gem counts demonstrates proper nuclear
localization, it is still unclear whether upregulating SMN levels
restore normal functionality.
Embedding the antisense sequence in an U7 snRNP complex
has several advantages over application of naked RNAs. First,
RNA splicing takes place in the nucleus where U7 snRNP particles
are located. Second, binding of U7-specific proteins and 59
capping of the U7 snRNA also ensures an increased half-life.
Third, the presence of U7 snRNA transgenes guarantees
continuous expression. These considerations make the use of
antisense oligonucleotides-embedded U7 snRNAs an attractive
approach, as was highlighted recently by the successful
application to modulate pre-mRNA processing in the dystro-
phin [24,25], SMN [26], and the thalassemic b-globin genes
[27]. Additional advantages can be gained by delivering these
antisense U7 snRNAs within viral vectors. We were able to
study the effects of antisense sequences in patient-derived
fibroblast cell lines, whereas transfection of these cells usually
results in toxicity, even when cationic transfection reagents are
used. Infection with viral vectors reaches the majority of cells
analyzed, while the efficiency of transient transfections is
limited. Importantly, adenoviruses can infect a broad range of
different mammalian cell lines and animal species without
integrating into the host cell genome [28]. Adv has a tropism
for neuronal cells and can be used to deliver transgenes to the
central nervous system [29,30,31]. Furthermore, Adv-5 is
replication deficient. The viral E1 gene is deleted from the
vector genome, thus the virus cannot replicate and can only be
grown in human embryonic kidney cells that are transformed
with the viral E1 gene. Accordingly, Adv-5 vectors have been
proposed for multiple gene therapy strategies and some have
been approved for clinical trials by the FDA [28,31].
It is not fully understood how the loss of the housekeeping
gene SMN1 leads to the selective loss of motoneurons in the
spinal cord. Recent studies have shown that in mouse spinal
cords the rate of ribonucleoprotein assembly is the highest
during myelination of the central nervous system. SMN plays an
essential role in this assembly process [7]. In a zebrafish model
of SMA it was shown that the addition of purified snRNPs could
rescue motoneuron impairment induced by the loss of SMN
[5,32]. Accordingly, reduced snRNP levels in SMA mice or
SMA fibroblast cell lines have been proposed to result in a
general pre-mRNA splicing defect [8,33]. Together these data
indicate that the window for effective treatment or prevention of
SMA might be very early during embryonic development.
Future efforts will concentrate on evaluating the anti-SMN U7
snRNA Adv-5 gene therapy approach in an animal model of
SMA. Importantly, the administration of the virus during
various stages of fetal development could pinpoint the optimal
time point for initiating treatment for SMA.
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Figure 4. Determination of changes in functional protein
levels following Adv-5/antisense U7 snRNA infection. (A)
SMA type-I fibroblast cells (G3813) were transduced with Adv-5
vectors either expressing antisense U7 snRNAs or control vectors
expressing SmOpt or GFP. The cell cultures were passaged for 10
days in 2% FBS medium, fixed with formaldehyde, and analyzed
using immunofluorescence. As an indicator for SMN levels the
fraction of nuclear gem-positive cells was determined by fluores-
cence microscopy. Cell nuclei are marked with white arrows. The
identity of the Adv-5 vectors is indicated on the left upper corner of
each panel. (B) The bar graph summarizes gem counts from 5
independent and blinded experiments. Standard deviations are
shown for each series. An asterisk above bars indicates a statistically
significant difference between the experimental series and the
SmOpt control series. A statistically significant difference between
series is definedb yp - v a l u e s,0.05. (C) Western blot analysis of
cell cultures infected with AdV5/U7 antisense snRNPs. G3813 cells
were transduced with AdV5/antisense U7 snRNPs at an MOI of
20. The expression levels were normalized to b-Actin using an
anti b-Actin monoclonal antibody. Relative SMN protein levels
were determined by SMN staining using a monoclonal anti SMN
antibody.
doi:10.1371/journal.pone.0008204.g004
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